FOLH1 and dry eye syndrome: Despite major consequences of PSMA radiotherapy with loss of saliva, taste, speech, and dry eyes, [225Ac]Ac-PSMA therapy is already being evaluated in the clinic with promising biochemical responses and low treatment-related toxicity [136].